Clinical Trial News

Phase I clinical trial of NH130, a selective serotonin 5-HT2A inverse agonist for Parkinson's disease psychosis, showed favorable pharmacokinetics and safety in healthy volunteers, with no serious adverse events reported. A physiologically based pharmacokinetic model accurately predicted NH130's behavior, supporting its potential as a therapeutic agent for Parkinson's disease psychosis.

Phase 3 trial initiated for oral cladribine in treating generalized myasthenia gravis, targeting B and T lymphocytes, potentially offering home administration and disease progression slowdown.

CellProthera's positive pre-IND meeting with FDA paves way for Phase III trial of ProtheraCytes, a cell therapy for myocardial infarction. The trial, with a two-year follow-up, aims to prevent subsequent heart diseases. The company plans to pursue RMAT designation for expedited development and review.

Orgenesis' ORG-101 CAR-T therapy showed efficacy and safety in 233 CD19+ B-cell ALL patients in China, with 82% CR rate in adults and 93% in children. Severe CRS was observed in 2% of adults and 6% of children. ORG-101 is produced via a decentralized approach and Orgenesis plans a multicenter phase 1/2 trial, starting in Greece.

Wegovy users had 33% lower Covid-19 death risk in a trial, with immediate protection before weight loss. All-cause death rates also dropped, suggesting obesity treatment improves life expectancy.

Eli Lilly announced retatrutide's trial results at ESC 2024, showing it reduced non-HDL-C, apoB, triglycerides, and improved lipid profiles in obese patients, potentially revolutionizing obesity treatment.

A rare, fatal disease called SPG50 affects fewer than 100 people globally, including 3-year-old Naomi Lockard. An experimental genetic therapy shows promise but is too expensive for most families. Naomi's mother, Rebekah Lockard, is raising funds for the therapy, which has shown success in stopping the disease's progression in clinical trials, but the trial has run out of funding.

The ABYSS trial suggests continuing beta-blockers may not be necessary for post-MI patients with preserved ejection fraction, but further research is needed. Results showed no safety preservation or quality of life benefits with beta-blocker interruption, with similar rates of death, MI, and stroke between groups, but higher rates of cardiovascular hospitalizations in the interruption group.

NIH grants $15.5m to establish NEXT STEPs network to include nursing home residents in clinical trials, led by Dr Kathleen Unroe, aiming to address their underrepresentation and enhance care quality.

A prospective, randomized, blind, crossover clinical trial involving healthy subjects evaluated the effects of dark and milk chocolate on retinal perfusion and vascular response using OCT-A and DVA. Subjects underwent ophthalmologic evaluations before and after chocolate consumption, with primary outcomes focusing on changes in retinal perfusion and vascular response to flicker stimulation post-dark chocolate intake. The study adhered to ethical standards and was approved by the San Raffaele Ethics Committee.